샘플 요청 목록

 카트 문의
시장보고서
상품코드
1794636

세계의 PARP(Poly ADP-Ribose Polymerase) 억제제 시장

Poly ADP-Ribose Polymerase (PARP) Inhibitors
발행일: | 리서치사: Market Glass, Inc. (Formerly Global Industry Analysts, Inc.) | 페이지 정보: 영문 284 Pages | 배송안내 : 1-2일 (영업일 기준)

    
    
    



※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

PARP(Poly ADP-Ribose Polymerase) 억제제 세계 시장은 2030년까지 349억 달러에 달할 전망

2024년에 108억 달러로 추정되는 PARP(Poly ADP-Ribose Polymerase) 억제제 세계 시장은 2024년부터 2030년까지 CAGR 21.7%로 성장하여 2030년에는 349억 달러에 달할 것으로 예측됩니다. 이 보고서에서 분석한 부문 중 하나인 소매 약국은 CAGR 23.1%를 기록하며 분석 기간 종료시에는 233억 달러에 달할 것으로 예측됩니다. 병원 약국 부문의 성장률은 분석 기간 동안 CAGR 19.6%로 추정됩니다.

미국 시장은 29억 달러로 추정, 중국은 CAGR 29.2%로 성장 예측

미국의 PARP(Poly ADP-Ribose Polymerase) 억제제 시장은 2024년에 29억 달러로 추정됩니다. 세계 2위 경제 대국인 중국은 2030년까지 84억 달러의 시장 규모에 달할 것으로 예측되며, 분석 기간인 2024-2030년 CAGR은 29.2%를 기록할 것으로 예상됩니다. 기타 주목할 만한 지역별 시장으로는 일본과 캐나다가 있고, 분석 기간 동안 CAGR은 각각 17.2%와 19.5%로 예측됩니다. 유럽에서는 독일이 CAGR 약 18.2%로 성장할 것으로 예측됩니다.

세계의 PARP(Poly ADP-Ribose Polymerase) 억제제 시장 - 주요 동향과 촉진요인 정리

DNA 복구 경로를 표적으로 하는 PARP 억제제가 암 치료의 패러다임을 재편하고 있습니다.

PARP 억제제가 고형암 관리에서 정밀 종양학에 혁명을 일으킬 수 있는 이유는 무엇일까?

폴리 ADP 리보스 중합효소(PARP) 억제제는 암세포의 DNA 복구 메커니즘을 파괴하여 상동결합결손증(HRD)을 가진 종양을 합성적으로 사멸시키는 표적항암제입니다. 이 경구용 약물은 단일 가닥 DNA 절단 복구에 중요한 역할을 하는 PARP 효소군을 선택적으로 억제하여, 기능적인 BRCA1/BRCA2 및 기타 복구 경로 단백질이 결여된 세포에서 치명적인 DNA 손상을 축적시킵니다. 그 결과, 정상세포를 보존하면서 종양세포를 선택적으로 사멸시킬 수 있어 맞춤형 의료에 큰 진전을 가져다 줄 수 있습니다. 당초 PARP 억제제는 BRCA 변이 난소암을 적응증으로 승인 받았으나, 현재는 유방암, 전립선암, 췌장암, 자궁내막암 등으로 적응증을 확대하고 있습니다. 승인된 주요 약제에는 올라파립(린파자), 니라파립(제줄라), 루카파립(루브라카), 타라조파립(타르젠나) 등이 있으며, 각각 고유한 약동학, 독성 프로파일, 투약 프로토콜을 가지고 있습니다. 이러한 치료법은 특히 HRD 양성 종양 환자를 대상으로 1차 치료와 유지요법 모두에서 치료의 기준을 재정의하고 있습니다. PARP 억제제의 치료적 장점은 기존 화학요법으로 충분히 치료할 수 없었던 유전적으로 정의된 종양 아형에 대응할 수 있다는 점입니다. 경구 투여와 우수한 독성 프로파일은 환자의 순응도를 더욱 높여 종양 포트폴리오에서 매력적인 선택이 될 수 있습니다.

PARP 억제제의 세계 보급을 주도하고 있는 암종과 환자군은?

난소암은 여전히 PARP 억제제 치료의 주요 적응증입니다. PARP 억제제를 이용한 유지요법은 BRCA 유전자 변이 및 광범위한 HRD 시그니처를 가진 환자의 무진행 생존기간을 최전선 및 재발 환자 모두에서 유의하게 연장시켰습니다. SOLO-1, PRIMA, ARIEL3 등의 임상 3상 시험을 바탕으로 약사법 승인을 확대하였습니다. 이러한 임상시험을 통해 BRCA 유전자 변이 및 HRD 양성인 하위 그룹에서 PARP 억제제의 유용성이 검증되어 임상적 유용성이 확대되었습니다. 유방암, 특히 생식세포 계열의 BRCA 유전자 변이가 있는 삼중음성 종양과 HER2 음성 종양에서 PARP 억제제는 화학요법 후 단독요법 또는 병용요법으로 지지받고 있습니다. OlympiAD 시험과 EMBRACA 시험은 그 효능을 뒷받침하는 확실한 증거를 제공했고, 전이 치료 경로에 통합되었습니다. 전이성 거세저항성 전립선암(mCRPC)의 경우, 특정 DNA 손상 복구(DDR) 유전자 변이가 있는 환자에게 올라파립과 루카파립과 같은 약물이 승인되면서 임상적 영향력이 더욱 확대되고 있습니다. 췌장암은 그동안 예후가 좋지 않아 치료 옵션이 제한적이었으나, PARP 억제제의 새로운 개척지로 떠오르고 있습니다. POLO 시험은 BRCA 돌연변이 종양 환자를 위한 유지요법으로서 올라파립의 유용성을 입증하여 이 악성종양에 있어 중요한 돌파구를 마련하였습니다. 또한, DNA 복구 이상이 존재하는 자궁내막암, 담관암, 소세포폐암에 대한 PARP의 효능이 실제 증거와 바스켓 시험을 통해 검토되고 있습니다.

임상 전략과 병용요법은 PARP 억제제의 유용성을 어떻게 높이고 있는가?

PARP 억제제를 둘러싼 임상 전략은 빠르게 진화하고 있으며, 면역관문억제제(ICI), 혈관신생억제제, 화학요법과의 병용요법을 평가하기 위한 임상시험이 진행 중입니다. 전임상 데이터는 PARP 억제가 cGAS-STING 경로를 활성화하여 종양의 면역원성을 높이고 PD-1/PD-L1 차단의 효능을 높인다는 것을 시사합니다. MEDIOLA와 TOPACIO와 같은 임상시험은 유방암과 난소암에서 이러한 시너지 효과를 평가하고 있습니다. 베바시주맙과 같은 VEGF 억제제와의 병용요법은 특히 백금제제 민감성 난소암에서 유망한 결과를 보이고 있습니다. PAOLA-1 시험에서 올라파립과 베바시주맙의 병용요법이 HRD 양성 환자의 PFS를 유의하게 연장하는 것으로 나타나 BRCA 변이종양 외의 다른 암종에서 PARP 억제제 사용을 지지하는 근거가 되었습니다. 다른 시험에서는 백금 제제 반응 후 PARP 억제제를 사용하거나, 탁산계 화학요법과 동시에 사용함으로써 임상적 유용성을 최적화하는 시퀀싱 전략이 검토되고 있습니다. 바이오마커 개발도 진행 중입니다. BRCA1/2 외에도 ATM, CHEK2, RAD51, PALB2의 변화가 PARP 감수성 예측 마커로 검증되고 있습니다. 유전체 불안정성 점수를 이용한 HRD 검사가 임상 워크플로우에 통합되어 적격 환자를 보다 정확하게 식별할 수 있도록 하고 있습니다. 동반진단약은 치료법의 승인과 함께 진화하고 있으며, 약물의 개발과 분자검사 인프라를 일치시키고 있습니다.

PARP 억제제의 세계 성장을 촉진하는 시장 촉진요인은 무엇인가?

PARP 억제제 시장의 성장은 정밀 종양학의 확대, 바이오마커에 기반한 환자 계층화, BRCA 양성 환자 증가 등 여러 가지 요인이 복합적으로 작용하여 이루어지고 있습니다. 가장 큰 원동력 중 하나는 맞춤형 암 치료로의 패러다임 전환입니다. 차세대 염기서열분석(NGS)이 암 치료의 표준으로 자리 잡으면서 HRD 관련 돌연변이를 가진 환자들이 더 많이 발견되고, PARP 억제제 시장이 확대되고 있습니다. 특히 난소암, 전립선암 등 일선에서 독성을 최소화한 유지요법에 대한 수요가 증가하면서 일선에서의 도입이 가속화되고 있습니다. 또한, 동반진단제 및 바이오마커 기반 처방에 대한 지불자의 지원이 증가함에 따라, 상환 장벽이 낮아져 지역 암 진료 및 신흥 의료 시스템에서 폭넓게 채택될 수 있게 되었습니다.

또한, 획기적 치료제 지정, 신속 승인, 국제 규제 조화로 인해 시장 진입이 가속화되고 있습니다. 아시아태평양 및 라틴아메리카의 신흥국들은 BRCA 검사에 대한 인식이 높아지고 치료 가이드라인에 포함되면서 PARP 억제제를 국가 암 대응 전략에 포함시키려는 움직임을 보이고 있습니다. PARP 억제제의 상업적 전망은 병용요법, 조기 적응증, 범암 바이오마커 승인 등이 파이프라인을 통해 진행됨에 따라 지속적으로 성장할 수 있는 여건이 조성되고 있습니다. PARP 억제제의 임상적 범용성 확대, 경구 투여 형태, 다른 표적 약물과의 시너지 효과로 인해 PARP 억제제는 미래 암 치료제의 중심이 될 것으로 보입니다.

부문

유통 채널(소매 약국, 병원 약국, 온라인 유통 채널), 최종사용(난소암 최종사용, 유방암 최종사용, 기타 최종사용)

조사 대상 기업 사례

  • AbbVie Inc.
  • Allarity Therapeutics Inc.
  • Artios Pharma
  • AstraZeneca Plc
  • Bayer AG
  • BeiGene Ltd.
  • Clovis Oncology(now part of Bristol Myers Squibb)
  • Daiichi Sankyo Co. Ltd.
  • Everest Pharmaceuticals Ltd.
  • GlaxoSmithKline Plc
  • IMPACT Therapeutics
  • Jeil Pharmaceuticals Co. Ltd.
  • Jiangsu Hengrui Pharmaceuticals Co. Ltd.
  • Johnson & Johnson Services, Inc.
  • Karyopharm Therapeutics Inc.
  • Merck & Co., Inc.
  • Ono Pharmaceutical Co. Ltd.
  • Pfizer Inc.
  • Repare Therapeutics Inc.
  • Zai Lab Ltd.

AI 통합

우리는 검증된 전문가 컨텐츠와 AI 툴을 통해 시장 정보와 경쟁 정보를 혁신하고 있습니다.

Global Industry Analysts는 LLM 및 업계 고유의 SLM을 조회하는 일반적인 규범을 따르는 대신 비디오 기록, 블로그, 검색 엔진 조사, 방대한 양의 기업, 제품/서비스, 시장 데이터 등 세계 전문가로부터 수집한 컨텐츠 리포지토리를 구축했습니다.

관세 영향 계수

Global Industry Analysts는 본사 소재지, 제조거점, 수출입(완제품 및 OEM)을 기준으로 기업의 경쟁력 변화를 예측하고 있습니다. 이러한 복잡하고 다면적인 시장 역학은 매출원가(COGS) 증가, 수익성 하락, 공급망 재편 등 미시적, 거시적 시장 역학 중에서도 특히 경쟁사들에게 영향을 미칠 것으로 예상됩니다.

목차

제1장 조사 방법

제2장 주요 요약

  • 시장 개요
  • 주요 기업
  • 시장 동향과 촉진요인
  • 세계 시장 전망

제3장 시장 분석

  • 미국
  • 캐나다
  • 일본
  • 중국
  • 유럽
  • 프랑스
  • 독일
  • 이탈리아
  • 영국
  • 스페인
  • 러시아
  • 기타 유럽
  • 아시아태평양
  • 호주
  • 인도
  • 한국
  • 기타 아시아태평양
  • 라틴아메리카
  • 아르헨티나
  • 브라질
  • 멕시코
  • 기타 라틴아메리카
  • 중동
  • 이란
  • 이스라엘
  • 사우디아라비아
  • 아랍에미리트
  • 기타 중동
  • 아프리카

제4장 경쟁

KSM 25.08.28

Global Poly ADP-Ribose Polymerase (PARP) Inhibitors Market to Reach US$34.9 Billion by 2030

The global market for Poly ADP-Ribose Polymerase (PARP) Inhibitors estimated at US$10.8 Billion in the year 2024, is expected to reach US$34.9 Billion by 2030, growing at a CAGR of 21.7% over the analysis period 2024-2030. Retail Pharmacies, one of the segments analyzed in the report, is expected to record a 23.1% CAGR and reach US$23.3 Billion by the end of the analysis period. Growth in the Hospital Pharmacies segment is estimated at 19.6% CAGR over the analysis period.

The U.S. Market is Estimated at US$2.9 Billion While China is Forecast to Grow at 29.2% CAGR

The Poly ADP-Ribose Polymerase (PARP) Inhibitors market in the U.S. is estimated at US$2.9 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$8.4 Billion by the year 2030 trailing a CAGR of 29.2% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 17.2% and 19.5% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 18.2% CAGR.

Global Poly ADP-Ribose Polymerase (PARP) Inhibitors Market - Key Trends & Drivers Summarized

Targeting DNA Repair Pathways: How PARP Inhibitors Are Reshaping Cancer Therapy Paradigms

Why Are PARP Inhibitors Revolutionizing Precision Oncology in Solid Tumor Management?

Poly ADP-ribose polymerase (PARP) inhibitors are a class of targeted cancer therapies that disrupt DNA repair mechanisms in cancer cells, leading to synthetic lethality in tumors with homologous recombination deficiencies (HRD). These oral agents selectively inhibit the PARP enzyme family-key players in repairing single-strand DNA breaks-thereby allowing lethal DNA damage to accumulate in cells lacking functional BRCA1/BRCA2 or other repair pathway proteins. The result is selective tumor cell death while sparing normal cells, offering a significant advancement in personalized medicine. Initially approved for BRCA-mutated ovarian cancer, PARP inhibitors have expanded into indications including breast, prostate, pancreatic, and endometrial cancers. Major approved agents include olaparib (Lynparza), niraparib (Zejula), rucaparib (Rubraca), and talazoparib (Talzenna), each with unique pharmacokinetics, toxicity profiles, and dosing protocols. These therapies have redefined treatment standards in both first-line and maintenance settings, particularly for patients with HRD-positive tumors. The therapeutic advantage of PARP inhibitors lies in their capacity to address genetically defined tumor subtypes that were previously underserved by conventional chemotherapy. Their oral administration and favorable toxicity profiles further enhance patient compliance, making them an attractive option in oncology portfolios.

Which Cancer Types and Patient Populations Are Driving the Adoption of PARP Inhibitors Globally?

Ovarian cancer remains the leading indication for PARP inhibitor therapy. In both frontline and recurrence settings, maintenance therapy with PARP inhibitors has significantly extended progression-free survival in patients with BRCA mutations or broader HRD signatures. Regulatory approvals have been expanded based on Phase III trials such as SOLO-1, PRIMA, and ARIEL3. These trials have validated the benefit of PARP inhibitors across BRCA-mutated and HRD-positive subgroups, broadening their clinical utility. In breast cancer, particularly triple-negative and HER2-negative tumors with germline BRCA mutations, PARP inhibitors have gained traction as monotherapy or combination therapy following chemotherapy. The OlympiAD and EMBRACA trials have provided robust evidence supporting their efficacy, leading to their integration into metastatic treatment pathways. In metastatic castration-resistant prostate cancer (mCRPC), agents like olaparib and rucaparib have been approved for patients with specific DNA damage repair (DDR) gene alterations, further expanding the clinical footprint of these agents. Pancreatic cancer, historically associated with poor prognosis and limited treatment options, has emerged as a new frontier for PARP inhibitors. The POLO trial demonstrated the utility of olaparib as a maintenance therapy for patients with BRCA-mutated tumors, representing a significant breakthrough in this notoriously aggressive malignancy. Additionally, real-world evidence and basket trials are exploring PARP efficacy in endometrial, bile duct, and small cell lung cancers where DNA repair defects are present.

How Are Clinical Strategies and Combination Therapies Enhancing PARP Inhibitor Utility?

The clinical strategy around PARP inhibitors is evolving rapidly with ongoing trials assessing their use in combination with immune checkpoint inhibitors (ICIs), anti-angiogenic agents, and chemotherapy. Preclinical data suggest that PARP inhibition increases tumor immunogenicity by activating cGAS-STING pathways, thereby enhancing the efficacy of PD-1/PD-L1 blockade. Trials like MEDIOLA and TOPACIO are evaluating this synergy in breast and ovarian cancers. Combination with VEGF inhibitors such as bevacizumab has shown promising outcomes, particularly in platinum-sensitive ovarian cancer. The PAOLA-1 trial demonstrated that olaparib plus bevacizumab extended PFS significantly in HRD-positive patients, supporting the use of PARP inhibitors beyond BRCA-mutated tumors. Additionally, studies are investigating sequencing strategies-using PARP inhibitors after platinum response or concurrently with taxane-based chemotherapy-to optimize clinical benefit. Biomarker development is also advancing. Beyond BRCA1/2, alterations in ATM, CHEK2, RAD51, and PALB2 are being validated as predictive markers of PARP sensitivity. HRD testing using genomic instability scores is being integrated into clinical workflows to identify eligible patients more accurately. Companion diagnostics are co-evolving with therapy approvals, aligning drug deployment with molecular testing infrastructure.

What Market Drivers Are Propelling the Global Growth of PARP Inhibitors?

The growth in the PARP inhibitors market is driven by multiple intersecting forces including precision oncology expansion, biomarker-based patient stratification, and increasing prevalence of BRCA-tested patients. One of the foremost drivers is the paradigm shift toward personalized cancer therapy. As next-generation sequencing (NGS) becomes standard practice in oncology, more patients are being identified with HRD-related mutations, expanding the addressable market for PARP inhibitors. The demand for maintenance therapies with minimal toxicity is accelerating uptake in frontline settings, particularly in ovarian and prostate cancers. Additionally, growing payer support for companion diagnostics and biomarker-guided prescribing is reducing reimbursement hurdles, enabling broader adoption across community oncology practices and emerging healthcare systems.

Regulatory support is also robust, with breakthrough therapy designations, fast-track approvals, and international regulatory harmonization accelerating market entry. Emerging economies in Asia-Pacific and Latin America are incorporating PARP inhibitors into national cancer control strategies, driven by rising awareness of BRCA testing and inclusion in treatment guidelines. As combination regimens, earlier-line indications, and pan-cancer biomarker approvals progress through pipelines, the commercial outlook for PARP inhibitors is poised for sustained growth. Their expanding clinical versatility, oral delivery format, and synergy with other targeted agents make them central to the future of oncology therapeutics.

SCOPE OF STUDY:

The report analyzes the Poly ADP-Ribose Polymerase (PARP) Inhibitors market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Distribution Channel (Retail Pharmacies, Hospital Pharmacies, Online Distribution Channel); End-Use (Ovarian Cancer End-Use, Breast Cancer End-Use, Other End-Uses)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 47 Featured) -

  • AbbVie Inc.
  • Allarity Therapeutics Inc.
  • Artios Pharma
  • AstraZeneca Plc
  • Bayer AG
  • BeiGene Ltd.
  • Clovis Oncology (now part of Bristol Myers Squibb)
  • Daiichi Sankyo Co. Ltd.
  • Everest Pharmaceuticals Ltd.
  • GlaxoSmithKline Plc
  • IMPACT Therapeutics
  • Jeil Pharmaceuticals Co. Ltd.
  • Jiangsu Hengrui Pharmaceuticals Co. Ltd.
  • Johnson & Johnson Services, Inc.
  • Karyopharm Therapeutics Inc.
  • Merck & Co., Inc.
  • Ono Pharmaceutical Co. Ltd.
  • Pfizer Inc.
  • Repare Therapeutics Inc.
  • Zai Lab Ltd.

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Tariff Impact on Global Supply Chain Patterns
    • Poly ADP-Ribose Polymerase (PARP) Inhibitors - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rising Incidence of Ovarian and Breast Cancers Expands Addressable Market for PARP Inhibitors
    • Growing Use of PARP Inhibitors in Precision Oncology Strengthens Business Case for Targeted Therapies
    • FDA and EMA Approvals of New Indications Propel Commercial Uptake Across Oncology Segments
    • Expansion of Companion Diagnostics Throws the Spotlight on Biomarker-Driven Treatment Protocols
    • Ongoing Clinical Trials in Prostate and Pancreatic Cancers Drive Indication Pipeline Diversification
    • Integration With Immuno-Oncology and Combination Therapies Enhances Treatment Efficacy
    • Rising Healthcare Spending in Emerging Markets Accelerates Global Access to PARP Inhibitors
    • Strategic Collaborations Between Pharma and Diagnostic Companies Fuel Development Synergies
    • Growth in Germline and Somatic Mutation Testing Supports Patient Stratification and Adoption
    • Patent Expiries and Generic Entry Pose Pricing Pressure and Market Disruption Risks
    • Increasing Reimbursement Approvals Across Oncology Centers Sustain Treatment Adoption
    • Technological Advancements in Drug Delivery Systems Improve Bioavailability and Patient Compliance
    • Focus on Long-Term Survival and Maintenance Therapies Drives Repeat Treatment Cycles
    • Regulatory Fast-Tracking of Breakthrough Therapies Enhances Speed-to-Market for New Entrants
    • Rise in Awareness Programs for BRCA-Mutated Cancers Strengthens Patient Outreach Efforts
    • Investments in Real-World Evidence and Outcome Studies Bolster Market Positioning
    • Expansion of Hospital-Based Oncology Infrastructure Promotes Institutional Procurement
    • Integration Into National Cancer Control Programs Facilitates Widespread Adoption
    • Pharmacovigilance and Post-Marketing Surveillance Requirements Create Compliance Complexity
    • Emerging Applications in Rare and Orphan Oncology Indications Unlock Niche Market Potential
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Poly ADP-Ribose Polymerase (PARP) Inhibitors Market Analysis of Annual Sales in US$ Million for Years 2014 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Poly ADP-Ribose Polymerase (PARP) Inhibitors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Poly ADP-Ribose Polymerase (PARP) Inhibitors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 4: World 16-Year Perspective for Poly ADP-Ribose Polymerase (PARP) Inhibitors by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2025 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Retail Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Retail Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 7: World 16-Year Perspective for Retail Pharmacies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Hospital Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Hospital Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 10: World 16-Year Perspective for Hospital Pharmacies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Online Distribution Channel by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Online Distribution Channel by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 13: World 16-Year Perspective for Online Distribution Channel by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Ovarian Cancer End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Ovarian Cancer End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 16: World 16-Year Perspective for Ovarian Cancer End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Breast Cancer End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Breast Cancer End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 19: World 16-Year Perspective for Breast Cancer End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 21: World Historic Review for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 22: World 16-Year Perspective for Other End-Uses by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Poly ADP-Ribose Polymerase (PARP) Inhibitors Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 23: USA Recent Past, Current & Future Analysis for Poly ADP-Ribose Polymerase (PARP) Inhibitors by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 24: USA Historic Review for Poly ADP-Ribose Polymerase (PARP) Inhibitors by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 25: USA 16-Year Perspective for Poly ADP-Ribose Polymerase (PARP) Inhibitors by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Hospital Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
    • TABLE 26: USA Recent Past, Current & Future Analysis for Poly ADP-Ribose Polymerase (PARP) Inhibitors by End-Use - Ovarian Cancer End-Use, Breast Cancer End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 27: USA Historic Review for Poly ADP-Ribose Polymerase (PARP) Inhibitors by End-Use - Ovarian Cancer End-Use, Breast Cancer End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 28: USA 16-Year Perspective for Poly ADP-Ribose Polymerase (PARP) Inhibitors by End-Use - Percentage Breakdown of Value Sales for Ovarian Cancer End-Use, Breast Cancer End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • CANADA
    • TABLE 29: Canada Recent Past, Current & Future Analysis for Poly ADP-Ribose Polymerase (PARP) Inhibitors by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 30: Canada Historic Review for Poly ADP-Ribose Polymerase (PARP) Inhibitors by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 31: Canada 16-Year Perspective for Poly ADP-Ribose Polymerase (PARP) Inhibitors by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Hospital Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
    • TABLE 32: Canada Recent Past, Current & Future Analysis for Poly ADP-Ribose Polymerase (PARP) Inhibitors by End-Use - Ovarian Cancer End-Use, Breast Cancer End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 33: Canada Historic Review for Poly ADP-Ribose Polymerase (PARP) Inhibitors by End-Use - Ovarian Cancer End-Use, Breast Cancer End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 34: Canada 16-Year Perspective for Poly ADP-Ribose Polymerase (PARP) Inhibitors by End-Use - Percentage Breakdown of Value Sales for Ovarian Cancer End-Use, Breast Cancer End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • JAPAN
    • Poly ADP-Ribose Polymerase (PARP) Inhibitors Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 35: Japan Recent Past, Current & Future Analysis for Poly ADP-Ribose Polymerase (PARP) Inhibitors by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 36: Japan Historic Review for Poly ADP-Ribose Polymerase (PARP) Inhibitors by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 37: Japan 16-Year Perspective for Poly ADP-Ribose Polymerase (PARP) Inhibitors by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Hospital Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
    • TABLE 38: Japan Recent Past, Current & Future Analysis for Poly ADP-Ribose Polymerase (PARP) Inhibitors by End-Use - Ovarian Cancer End-Use, Breast Cancer End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 39: Japan Historic Review for Poly ADP-Ribose Polymerase (PARP) Inhibitors by End-Use - Ovarian Cancer End-Use, Breast Cancer End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 40: Japan 16-Year Perspective for Poly ADP-Ribose Polymerase (PARP) Inhibitors by End-Use - Percentage Breakdown of Value Sales for Ovarian Cancer End-Use, Breast Cancer End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • CHINA
    • Poly ADP-Ribose Polymerase (PARP) Inhibitors Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 41: China Recent Past, Current & Future Analysis for Poly ADP-Ribose Polymerase (PARP) Inhibitors by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 42: China Historic Review for Poly ADP-Ribose Polymerase (PARP) Inhibitors by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 43: China 16-Year Perspective for Poly ADP-Ribose Polymerase (PARP) Inhibitors by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Hospital Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
    • TABLE 44: China Recent Past, Current & Future Analysis for Poly ADP-Ribose Polymerase (PARP) Inhibitors by End-Use - Ovarian Cancer End-Use, Breast Cancer End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 45: China Historic Review for Poly ADP-Ribose Polymerase (PARP) Inhibitors by End-Use - Ovarian Cancer End-Use, Breast Cancer End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 46: China 16-Year Perspective for Poly ADP-Ribose Polymerase (PARP) Inhibitors by End-Use - Percentage Breakdown of Value Sales for Ovarian Cancer End-Use, Breast Cancer End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • EUROPE
    • Poly ADP-Ribose Polymerase (PARP) Inhibitors Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 47: Europe Recent Past, Current & Future Analysis for Poly ADP-Ribose Polymerase (PARP) Inhibitors by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 48: Europe Historic Review for Poly ADP-Ribose Polymerase (PARP) Inhibitors by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 49: Europe 16-Year Perspective for Poly ADP-Ribose Polymerase (PARP) Inhibitors by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2025 & 2030
    • TABLE 50: Europe Recent Past, Current & Future Analysis for Poly ADP-Ribose Polymerase (PARP) Inhibitors by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 51: Europe Historic Review for Poly ADP-Ribose Polymerase (PARP) Inhibitors by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 52: Europe 16-Year Perspective for Poly ADP-Ribose Polymerase (PARP) Inhibitors by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Hospital Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
    • TABLE 53: Europe Recent Past, Current & Future Analysis for Poly ADP-Ribose Polymerase (PARP) Inhibitors by End-Use - Ovarian Cancer End-Use, Breast Cancer End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 54: Europe Historic Review for Poly ADP-Ribose Polymerase (PARP) Inhibitors by End-Use - Ovarian Cancer End-Use, Breast Cancer End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 55: Europe 16-Year Perspective for Poly ADP-Ribose Polymerase (PARP) Inhibitors by End-Use - Percentage Breakdown of Value Sales for Ovarian Cancer End-Use, Breast Cancer End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • FRANCE
    • Poly ADP-Ribose Polymerase (PARP) Inhibitors Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 56: France Recent Past, Current & Future Analysis for Poly ADP-Ribose Polymerase (PARP) Inhibitors by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 57: France Historic Review for Poly ADP-Ribose Polymerase (PARP) Inhibitors by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 58: France 16-Year Perspective for Poly ADP-Ribose Polymerase (PARP) Inhibitors by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Hospital Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
    • TABLE 59: France Recent Past, Current & Future Analysis for Poly ADP-Ribose Polymerase (PARP) Inhibitors by End-Use - Ovarian Cancer End-Use, Breast Cancer End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 60: France Historic Review for Poly ADP-Ribose Polymerase (PARP) Inhibitors by End-Use - Ovarian Cancer End-Use, Breast Cancer End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 61: France 16-Year Perspective for Poly ADP-Ribose Polymerase (PARP) Inhibitors by End-Use - Percentage Breakdown of Value Sales for Ovarian Cancer End-Use, Breast Cancer End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • GERMANY
    • Poly ADP-Ribose Polymerase (PARP) Inhibitors Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 62: Germany Recent Past, Current & Future Analysis for Poly ADP-Ribose Polymerase (PARP) Inhibitors by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 63: Germany Historic Review for Poly ADP-Ribose Polymerase (PARP) Inhibitors by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 64: Germany 16-Year Perspective for Poly ADP-Ribose Polymerase (PARP) Inhibitors by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Hospital Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
    • TABLE 65: Germany Recent Past, Current & Future Analysis for Poly ADP-Ribose Polymerase (PARP) Inhibitors by End-Use - Ovarian Cancer End-Use, Breast Cancer End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 66: Germany Historic Review for Poly ADP-Ribose Polymerase (PARP) Inhibitors by End-Use - Ovarian Cancer End-Use, Breast Cancer End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 67: Germany 16-Year Perspective for Poly ADP-Ribose Polymerase (PARP) Inhibitors by End-Use - Percentage Breakdown of Value Sales for Ovarian Cancer End-Use, Breast Cancer End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • ITALY
    • TABLE 68: Italy Recent Past, Current & Future Analysis for Poly ADP-Ribose Polymerase (PARP) Inhibitors by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 69: Italy Historic Review for Poly ADP-Ribose Polymerase (PARP) Inhibitors by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 70: Italy 16-Year Perspective for Poly ADP-Ribose Polymerase (PARP) Inhibitors by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Hospital Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
    • TABLE 71: Italy Recent Past, Current & Future Analysis for Poly ADP-Ribose Polymerase (PARP) Inhibitors by End-Use - Ovarian Cancer End-Use, Breast Cancer End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 72: Italy Historic Review for Poly ADP-Ribose Polymerase (PARP) Inhibitors by End-Use - Ovarian Cancer End-Use, Breast Cancer End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 73: Italy 16-Year Perspective for Poly ADP-Ribose Polymerase (PARP) Inhibitors by End-Use - Percentage Breakdown of Value Sales for Ovarian Cancer End-Use, Breast Cancer End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • UNITED KINGDOM
    • Poly ADP-Ribose Polymerase (PARP) Inhibitors Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 74: UK Recent Past, Current & Future Analysis for Poly ADP-Ribose Polymerase (PARP) Inhibitors by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 75: UK Historic Review for Poly ADP-Ribose Polymerase (PARP) Inhibitors by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 76: UK 16-Year Perspective for Poly ADP-Ribose Polymerase (PARP) Inhibitors by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Hospital Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
    • TABLE 77: UK Recent Past, Current & Future Analysis for Poly ADP-Ribose Polymerase (PARP) Inhibitors by End-Use - Ovarian Cancer End-Use, Breast Cancer End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 78: UK Historic Review for Poly ADP-Ribose Polymerase (PARP) Inhibitors by End-Use - Ovarian Cancer End-Use, Breast Cancer End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 79: UK 16-Year Perspective for Poly ADP-Ribose Polymerase (PARP) Inhibitors by End-Use - Percentage Breakdown of Value Sales for Ovarian Cancer End-Use, Breast Cancer End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • SPAIN
    • TABLE 80: Spain Recent Past, Current & Future Analysis for Poly ADP-Ribose Polymerase (PARP) Inhibitors by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 81: Spain Historic Review for Poly ADP-Ribose Polymerase (PARP) Inhibitors by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 82: Spain 16-Year Perspective for Poly ADP-Ribose Polymerase (PARP) Inhibitors by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Hospital Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
    • TABLE 83: Spain Recent Past, Current & Future Analysis for Poly ADP-Ribose Polymerase (PARP) Inhibitors by End-Use - Ovarian Cancer End-Use, Breast Cancer End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 84: Spain Historic Review for Poly ADP-Ribose Polymerase (PARP) Inhibitors by End-Use - Ovarian Cancer End-Use, Breast Cancer End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 85: Spain 16-Year Perspective for Poly ADP-Ribose Polymerase (PARP) Inhibitors by End-Use - Percentage Breakdown of Value Sales for Ovarian Cancer End-Use, Breast Cancer End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • RUSSIA
    • TABLE 86: Russia Recent Past, Current & Future Analysis for Poly ADP-Ribose Polymerase (PARP) Inhibitors by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 87: Russia Historic Review for Poly ADP-Ribose Polymerase (PARP) Inhibitors by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 88: Russia 16-Year Perspective for Poly ADP-Ribose Polymerase (PARP) Inhibitors by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Hospital Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
    • TABLE 89: Russia Recent Past, Current & Future Analysis for Poly ADP-Ribose Polymerase (PARP) Inhibitors by End-Use - Ovarian Cancer End-Use, Breast Cancer End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 90: Russia Historic Review for Poly ADP-Ribose Polymerase (PARP) Inhibitors by End-Use - Ovarian Cancer End-Use, Breast Cancer End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 91: Russia 16-Year Perspective for Poly ADP-Ribose Polymerase (PARP) Inhibitors by End-Use - Percentage Breakdown of Value Sales for Ovarian Cancer End-Use, Breast Cancer End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • REST OF EUROPE
    • TABLE 92: Rest of Europe Recent Past, Current & Future Analysis for Poly ADP-Ribose Polymerase (PARP) Inhibitors by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 93: Rest of Europe Historic Review for Poly ADP-Ribose Polymerase (PARP) Inhibitors by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 94: Rest of Europe 16-Year Perspective for Poly ADP-Ribose Polymerase (PARP) Inhibitors by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Hospital Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
    • TABLE 95: Rest of Europe Recent Past, Current & Future Analysis for Poly ADP-Ribose Polymerase (PARP) Inhibitors by End-Use - Ovarian Cancer End-Use, Breast Cancer End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 96: Rest of Europe Historic Review for Poly ADP-Ribose Polymerase (PARP) Inhibitors by End-Use - Ovarian Cancer End-Use, Breast Cancer End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 97: Rest of Europe 16-Year Perspective for Poly ADP-Ribose Polymerase (PARP) Inhibitors by End-Use - Percentage Breakdown of Value Sales for Ovarian Cancer End-Use, Breast Cancer End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • ASIA-PACIFIC
    • Poly ADP-Ribose Polymerase (PARP) Inhibitors Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 98: Asia-Pacific Recent Past, Current & Future Analysis for Poly ADP-Ribose Polymerase (PARP) Inhibitors by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 99: Asia-Pacific Historic Review for Poly ADP-Ribose Polymerase (PARP) Inhibitors by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 100: Asia-Pacific 16-Year Perspective for Poly ADP-Ribose Polymerase (PARP) Inhibitors by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2025 & 2030
    • TABLE 101: Asia-Pacific Recent Past, Current & Future Analysis for Poly ADP-Ribose Polymerase (PARP) Inhibitors by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 102: Asia-Pacific Historic Review for Poly ADP-Ribose Polymerase (PARP) Inhibitors by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 103: Asia-Pacific 16-Year Perspective for Poly ADP-Ribose Polymerase (PARP) Inhibitors by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Hospital Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
    • TABLE 104: Asia-Pacific Recent Past, Current & Future Analysis for Poly ADP-Ribose Polymerase (PARP) Inhibitors by End-Use - Ovarian Cancer End-Use, Breast Cancer End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 105: Asia-Pacific Historic Review for Poly ADP-Ribose Polymerase (PARP) Inhibitors by End-Use - Ovarian Cancer End-Use, Breast Cancer End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 106: Asia-Pacific 16-Year Perspective for Poly ADP-Ribose Polymerase (PARP) Inhibitors by End-Use - Percentage Breakdown of Value Sales for Ovarian Cancer End-Use, Breast Cancer End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • AUSTRALIA
    • Poly ADP-Ribose Polymerase (PARP) Inhibitors Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
    • TABLE 107: Australia Recent Past, Current & Future Analysis for Poly ADP-Ribose Polymerase (PARP) Inhibitors by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 108: Australia Historic Review for Poly ADP-Ribose Polymerase (PARP) Inhibitors by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 109: Australia 16-Year Perspective for Poly ADP-Ribose Polymerase (PARP) Inhibitors by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Hospital Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
    • TABLE 110: Australia Recent Past, Current & Future Analysis for Poly ADP-Ribose Polymerase (PARP) Inhibitors by End-Use - Ovarian Cancer End-Use, Breast Cancer End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 111: Australia Historic Review for Poly ADP-Ribose Polymerase (PARP) Inhibitors by End-Use - Ovarian Cancer End-Use, Breast Cancer End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 112: Australia 16-Year Perspective for Poly ADP-Ribose Polymerase (PARP) Inhibitors by End-Use - Percentage Breakdown of Value Sales for Ovarian Cancer End-Use, Breast Cancer End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • INDIA
    • Poly ADP-Ribose Polymerase (PARP) Inhibitors Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
    • TABLE 113: India Recent Past, Current & Future Analysis for Poly ADP-Ribose Polymerase (PARP) Inhibitors by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 114: India Historic Review for Poly ADP-Ribose Polymerase (PARP) Inhibitors by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 115: India 16-Year Perspective for Poly ADP-Ribose Polymerase (PARP) Inhibitors by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Hospital Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
    • TABLE 116: India Recent Past, Current & Future Analysis for Poly ADP-Ribose Polymerase (PARP) Inhibitors by End-Use - Ovarian Cancer End-Use, Breast Cancer End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 117: India Historic Review for Poly ADP-Ribose Polymerase (PARP) Inhibitors by End-Use - Ovarian Cancer End-Use, Breast Cancer End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 118: India 16-Year Perspective for Poly ADP-Ribose Polymerase (PARP) Inhibitors by End-Use - Percentage Breakdown of Value Sales for Ovarian Cancer End-Use, Breast Cancer End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • SOUTH KOREA
    • TABLE 119: South Korea Recent Past, Current & Future Analysis for Poly ADP-Ribose Polymerase (PARP) Inhibitors by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 120: South Korea Historic Review for Poly ADP-Ribose Polymerase (PARP) Inhibitors by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 121: South Korea 16-Year Perspective for Poly ADP-Ribose Polymerase (PARP) Inhibitors by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Hospital Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
    • TABLE 122: South Korea Recent Past, Current & Future Analysis for Poly ADP-Ribose Polymerase (PARP) Inhibitors by End-Use - Ovarian Cancer End-Use, Breast Cancer End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 123: South Korea Historic Review for Poly ADP-Ribose Polymerase (PARP) Inhibitors by End-Use - Ovarian Cancer End-Use, Breast Cancer End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 124: South Korea 16-Year Perspective for Poly ADP-Ribose Polymerase (PARP) Inhibitors by End-Use - Percentage Breakdown of Value Sales for Ovarian Cancer End-Use, Breast Cancer End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 125: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Poly ADP-Ribose Polymerase (PARP) Inhibitors by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 126: Rest of Asia-Pacific Historic Review for Poly ADP-Ribose Polymerase (PARP) Inhibitors by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 127: Rest of Asia-Pacific 16-Year Perspective for Poly ADP-Ribose Polymerase (PARP) Inhibitors by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Hospital Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
    • TABLE 128: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Poly ADP-Ribose Polymerase (PARP) Inhibitors by End-Use - Ovarian Cancer End-Use, Breast Cancer End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 129: Rest of Asia-Pacific Historic Review for Poly ADP-Ribose Polymerase (PARP) Inhibitors by End-Use - Ovarian Cancer End-Use, Breast Cancer End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 130: Rest of Asia-Pacific 16-Year Perspective for Poly ADP-Ribose Polymerase (PARP) Inhibitors by End-Use - Percentage Breakdown of Value Sales for Ovarian Cancer End-Use, Breast Cancer End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • LATIN AMERICA
    • Poly ADP-Ribose Polymerase (PARP) Inhibitors Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
    • TABLE 131: Latin America Recent Past, Current & Future Analysis for Poly ADP-Ribose Polymerase (PARP) Inhibitors by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 132: Latin America Historic Review for Poly ADP-Ribose Polymerase (PARP) Inhibitors by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 133: Latin America 16-Year Perspective for Poly ADP-Ribose Polymerase (PARP) Inhibitors by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2014, 2025 & 2030
    • TABLE 134: Latin America Recent Past, Current & Future Analysis for Poly ADP-Ribose Polymerase (PARP) Inhibitors by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 135: Latin America Historic Review for Poly ADP-Ribose Polymerase (PARP) Inhibitors by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 136: Latin America 16-Year Perspective for Poly ADP-Ribose Polymerase (PARP) Inhibitors by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Hospital Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
    • TABLE 137: Latin America Recent Past, Current & Future Analysis for Poly ADP-Ribose Polymerase (PARP) Inhibitors by End-Use - Ovarian Cancer End-Use, Breast Cancer End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 138: Latin America Historic Review for Poly ADP-Ribose Polymerase (PARP) Inhibitors by End-Use - Ovarian Cancer End-Use, Breast Cancer End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 139: Latin America 16-Year Perspective for Poly ADP-Ribose Polymerase (PARP) Inhibitors by End-Use - Percentage Breakdown of Value Sales for Ovarian Cancer End-Use, Breast Cancer End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • ARGENTINA
    • TABLE 140: Argentina Recent Past, Current & Future Analysis for Poly ADP-Ribose Polymerase (PARP) Inhibitors by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 141: Argentina Historic Review for Poly ADP-Ribose Polymerase (PARP) Inhibitors by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 142: Argentina 16-Year Perspective for Poly ADP-Ribose Polymerase (PARP) Inhibitors by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Hospital Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
    • TABLE 143: Argentina Recent Past, Current & Future Analysis for Poly ADP-Ribose Polymerase (PARP) Inhibitors by End-Use - Ovarian Cancer End-Use, Breast Cancer End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 144: Argentina Historic Review for Poly ADP-Ribose Polymerase (PARP) Inhibitors by End-Use - Ovarian Cancer End-Use, Breast Cancer End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 145: Argentina 16-Year Perspective for Poly ADP-Ribose Polymerase (PARP) Inhibitors by End-Use - Percentage Breakdown of Value Sales for Ovarian Cancer End-Use, Breast Cancer End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • BRAZIL
    • TABLE 146: Brazil Recent Past, Current & Future Analysis for Poly ADP-Ribose Polymerase (PARP) Inhibitors by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 147: Brazil Historic Review for Poly ADP-Ribose Polymerase (PARP) Inhibitors by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 148: Brazil 16-Year Perspective for Poly ADP-Ribose Polymerase (PARP) Inhibitors by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Hospital Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
    • TABLE 149: Brazil Recent Past, Current & Future Analysis for Poly ADP-Ribose Polymerase (PARP) Inhibitors by End-Use - Ovarian Cancer End-Use, Breast Cancer End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 150: Brazil Historic Review for Poly ADP-Ribose Polymerase (PARP) Inhibitors by End-Use - Ovarian Cancer End-Use, Breast Cancer End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 151: Brazil 16-Year Perspective for Poly ADP-Ribose Polymerase (PARP) Inhibitors by End-Use - Percentage Breakdown of Value Sales for Ovarian Cancer End-Use, Breast Cancer End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • MEXICO
    • TABLE 152: Mexico Recent Past, Current & Future Analysis for Poly ADP-Ribose Polymerase (PARP) Inhibitors by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 153: Mexico Historic Review for Poly ADP-Ribose Polymerase (PARP) Inhibitors by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 154: Mexico 16-Year Perspective for Poly ADP-Ribose Polymerase (PARP) Inhibitors by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Hospital Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
    • TABLE 155: Mexico Recent Past, Current & Future Analysis for Poly ADP-Ribose Polymerase (PARP) Inhibitors by End-Use - Ovarian Cancer End-Use, Breast Cancer End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 156: Mexico Historic Review for Poly ADP-Ribose Polymerase (PARP) Inhibitors by End-Use - Ovarian Cancer End-Use, Breast Cancer End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 157: Mexico 16-Year Perspective for Poly ADP-Ribose Polymerase (PARP) Inhibitors by End-Use - Percentage Breakdown of Value Sales for Ovarian Cancer End-Use, Breast Cancer End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • REST OF LATIN AMERICA
    • TABLE 158: Rest of Latin America Recent Past, Current & Future Analysis for Poly ADP-Ribose Polymerase (PARP) Inhibitors by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 159: Rest of Latin America Historic Review for Poly ADP-Ribose Polymerase (PARP) Inhibitors by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 160: Rest of Latin America 16-Year Perspective for Poly ADP-Ribose Polymerase (PARP) Inhibitors by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Hospital Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
    • TABLE 161: Rest of Latin America Recent Past, Current & Future Analysis for Poly ADP-Ribose Polymerase (PARP) Inhibitors by End-Use - Ovarian Cancer End-Use, Breast Cancer End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 162: Rest of Latin America Historic Review for Poly ADP-Ribose Polymerase (PARP) Inhibitors by End-Use - Ovarian Cancer End-Use, Breast Cancer End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 163: Rest of Latin America 16-Year Perspective for Poly ADP-Ribose Polymerase (PARP) Inhibitors by End-Use - Percentage Breakdown of Value Sales for Ovarian Cancer End-Use, Breast Cancer End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • MIDDLE EAST
    • Poly ADP-Ribose Polymerase (PARP) Inhibitors Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
    • TABLE 164: Middle East Recent Past, Current & Future Analysis for Poly ADP-Ribose Polymerase (PARP) Inhibitors by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 165: Middle East Historic Review for Poly ADP-Ribose Polymerase (PARP) Inhibitors by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 166: Middle East 16-Year Perspective for Poly ADP-Ribose Polymerase (PARP) Inhibitors by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2014, 2025 & 2030
    • TABLE 167: Middle East Recent Past, Current & Future Analysis for Poly ADP-Ribose Polymerase (PARP) Inhibitors by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 168: Middle East Historic Review for Poly ADP-Ribose Polymerase (PARP) Inhibitors by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 169: Middle East 16-Year Perspective for Poly ADP-Ribose Polymerase (PARP) Inhibitors by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Hospital Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
    • TABLE 170: Middle East Recent Past, Current & Future Analysis for Poly ADP-Ribose Polymerase (PARP) Inhibitors by End-Use - Ovarian Cancer End-Use, Breast Cancer End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 171: Middle East Historic Review for Poly ADP-Ribose Polymerase (PARP) Inhibitors by End-Use - Ovarian Cancer End-Use, Breast Cancer End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 172: Middle East 16-Year Perspective for Poly ADP-Ribose Polymerase (PARP) Inhibitors by End-Use - Percentage Breakdown of Value Sales for Ovarian Cancer End-Use, Breast Cancer End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • IRAN
    • TABLE 173: Iran Recent Past, Current & Future Analysis for Poly ADP-Ribose Polymerase (PARP) Inhibitors by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 174: Iran Historic Review for Poly ADP-Ribose Polymerase (PARP) Inhibitors by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 175: Iran 16-Year Perspective for Poly ADP-Ribose Polymerase (PARP) Inhibitors by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Hospital Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
    • TABLE 176: Iran Recent Past, Current & Future Analysis for Poly ADP-Ribose Polymerase (PARP) Inhibitors by End-Use - Ovarian Cancer End-Use, Breast Cancer End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 177: Iran Historic Review for Poly ADP-Ribose Polymerase (PARP) Inhibitors by End-Use - Ovarian Cancer End-Use, Breast Cancer End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 178: Iran 16-Year Perspective for Poly ADP-Ribose Polymerase (PARP) Inhibitors by End-Use - Percentage Breakdown of Value Sales for Ovarian Cancer End-Use, Breast Cancer End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • ISRAEL
    • TABLE 179: Israel Recent Past, Current & Future Analysis for Poly ADP-Ribose Polymerase (PARP) Inhibitors by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 180: Israel Historic Review for Poly ADP-Ribose Polymerase (PARP) Inhibitors by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 181: Israel 16-Year Perspective for Poly ADP-Ribose Polymerase (PARP) Inhibitors by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Hospital Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
    • TABLE 182: Israel Recent Past, Current & Future Analysis for Poly ADP-Ribose Polymerase (PARP) Inhibitors by End-Use - Ovarian Cancer End-Use, Breast Cancer End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 183: Israel Historic Review for Poly ADP-Ribose Polymerase (PARP) Inhibitors by End-Use - Ovarian Cancer End-Use, Breast Cancer End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 184: Israel 16-Year Perspective for Poly ADP-Ribose Polymerase (PARP) Inhibitors by End-Use - Percentage Breakdown of Value Sales for Ovarian Cancer End-Use, Breast Cancer End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • SAUDI ARABIA
    • TABLE 185: Saudi Arabia Recent Past, Current & Future Analysis for Poly ADP-Ribose Polymerase (PARP) Inhibitors by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 186: Saudi Arabia Historic Review for Poly ADP-Ribose Polymerase (PARP) Inhibitors by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 187: Saudi Arabia 16-Year Perspective for Poly ADP-Ribose Polymerase (PARP) Inhibitors by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Hospital Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
    • TABLE 188: Saudi Arabia Recent Past, Current & Future Analysis for Poly ADP-Ribose Polymerase (PARP) Inhibitors by End-Use - Ovarian Cancer End-Use, Breast Cancer End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 189: Saudi Arabia Historic Review for Poly ADP-Ribose Polymerase (PARP) Inhibitors by End-Use - Ovarian Cancer End-Use, Breast Cancer End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 190: Saudi Arabia 16-Year Perspective for Poly ADP-Ribose Polymerase (PARP) Inhibitors by End-Use - Percentage Breakdown of Value Sales for Ovarian Cancer End-Use, Breast Cancer End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 191: UAE Recent Past, Current & Future Analysis for Poly ADP-Ribose Polymerase (PARP) Inhibitors by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 192: UAE Historic Review for Poly ADP-Ribose Polymerase (PARP) Inhibitors by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 193: UAE 16-Year Perspective for Poly ADP-Ribose Polymerase (PARP) Inhibitors by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Hospital Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
    • TABLE 194: UAE Recent Past, Current & Future Analysis for Poly ADP-Ribose Polymerase (PARP) Inhibitors by End-Use - Ovarian Cancer End-Use, Breast Cancer End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 195: UAE Historic Review for Poly ADP-Ribose Polymerase (PARP) Inhibitors by End-Use - Ovarian Cancer End-Use, Breast Cancer End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 196: UAE 16-Year Perspective for Poly ADP-Ribose Polymerase (PARP) Inhibitors by End-Use - Percentage Breakdown of Value Sales for Ovarian Cancer End-Use, Breast Cancer End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • REST OF MIDDLE EAST
    • TABLE 197: Rest of Middle East Recent Past, Current & Future Analysis for Poly ADP-Ribose Polymerase (PARP) Inhibitors by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 198: Rest of Middle East Historic Review for Poly ADP-Ribose Polymerase (PARP) Inhibitors by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 199: Rest of Middle East 16-Year Perspective for Poly ADP-Ribose Polymerase (PARP) Inhibitors by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Hospital Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
    • TABLE 200: Rest of Middle East Recent Past, Current & Future Analysis for Poly ADP-Ribose Polymerase (PARP) Inhibitors by End-Use - Ovarian Cancer End-Use, Breast Cancer End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 201: Rest of Middle East Historic Review for Poly ADP-Ribose Polymerase (PARP) Inhibitors by End-Use - Ovarian Cancer End-Use, Breast Cancer End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 202: Rest of Middle East 16-Year Perspective for Poly ADP-Ribose Polymerase (PARP) Inhibitors by End-Use - Percentage Breakdown of Value Sales for Ovarian Cancer End-Use, Breast Cancer End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • AFRICA
    • Poly ADP-Ribose Polymerase (PARP) Inhibitors Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
    • TABLE 203: Africa Recent Past, Current & Future Analysis for Poly ADP-Ribose Polymerase (PARP) Inhibitors by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 204: Africa Historic Review for Poly ADP-Ribose Polymerase (PARP) Inhibitors by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 205: Africa 16-Year Perspective for Poly ADP-Ribose Polymerase (PARP) Inhibitors by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Hospital Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
    • TABLE 206: Africa Recent Past, Current & Future Analysis for Poly ADP-Ribose Polymerase (PARP) Inhibitors by End-Use - Ovarian Cancer End-Use, Breast Cancer End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 207: Africa Historic Review for Poly ADP-Ribose Polymerase (PARP) Inhibitors by End-Use - Ovarian Cancer End-Use, Breast Cancer End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 208: Africa 16-Year Perspective for Poly ADP-Ribose Polymerase (PARP) Inhibitors by End-Use - Percentage Breakdown of Value Sales for Ovarian Cancer End-Use, Breast Cancer End-Use and Other End-Uses for the Years 2014, 2025 & 2030

IV. COMPETITION

샘플 요청 목록
0 건의 상품을 선택 중
목록 보기
전체삭제